PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10988358-2	2000	In vivo studies demonstrated that pretreatment of mice with DFX reduces tumor necrosis factor alpha (TNF-alpha) serum levels and increases the rate of survival of mice inoculated with lethal doses of lipopolysaccharide (LPS) or Escherichia coli O111:B4.	Deferoxamine	60-63	tumor necrosis factor	Mus musculus	72-99	
10988358-2	2000	In vivo studies demonstrated that pretreatment of mice with DFX reduces tumor necrosis factor alpha (TNF-alpha) serum levels and increases the rate of survival of mice inoculated with lethal doses of lipopolysaccharide (LPS) or Escherichia coli O111:B4.	Deferoxamine	60-63	tumor necrosis factor	Mus musculus	101-110	
10988358-4	2000	On the other hand, DFX prevents mortality induced either by LPS or murine recombinant TNF-alpha in D(+)-galactosamine (GalN)-sensitized mice.	Deferoxamine	19-22	tumor necrosis factor	Mus musculus	86-95	
10988358-5	2000	These protective actions of DFX correlate with an attenuated tissue damage observed in lungs, livers and kidneys of LPS-treated animals and GalN-sensitized mice inoculated with TNF-alpha.	Deferoxamine	28-31	tumor necrosis factor	Mus musculus	177-186